

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors EFFECTIVE: 01/01/2021	
ICD-10 Code[^]	Explanation of Code
C00.- - C43.-, C4A.-, C45.- - C48.-, C49.- - C96.-	Malignant neoplasms (excluding category C44 and C49.A), stated or presumed to be primary (of specified site) and certain specified histologies NEW for FY2018: <i>C96.20 Malignant mast cell neoplasm, unspecified C96.21 Aggressive systemic mastocytosis C96.22 Mast cell sarcoma C96.29 Other malignant cell neoplasm</i>
C44.00, C44.09	Unspecified/other malignant neoplasm of skin of lip
C44.10-, C44.19-	Unspecified/other malignant neoplasm of skin of eyelid
C44.13-	Sebaceous cell carcinoma of skin of eyelid, including canthus Note: Effective 10/1/2018
C44.20-, C44.29-	Unspecified/other malignant neoplasm skin of ear and external auricular canal
C44.30-, C44.39-	Unspecified/other malignant neoplasm of skin of other/unspecified parts of face
C44.40, C44.49	Unspecified/other malignant neoplasm of skin of scalp & neck
C44.50-, C44.59-	Unspecified/other malignant neoplasm of skin of trunk
C44.60-, C44.69-	Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder
C44.70-, C44.79-	Unspecified/other malignant neoplasm of skin of lower limb, including hip
C44.80, C44.89	Unspecified/other malignant neoplasm of skin of overlapping sites of skin
C44.90, C44.99	Unspecified/other malignant neoplasm of skin of unspecified sites of skin
C49.A-	Gastrointestinal Stromal Tumors Note: All GIST tumors are now reportable starting in 2021 (per ICD-O-3.2), including GIST, NOS
D00.- - D09.-	In-situ neoplasms: Note: Carcinoma in situ of the cervix (CIN III-8077/2) and Prostatic Intraepithelial Carcinoma (PIN III-8148/2) are not reportable. *Vulvar intraepithelial neoplasm III (VIN III), Vaginal intraepithelial neoplasm III (VAIN III), and Anal intraepithelial neoplasm III (AIN III) are reportable in Washington State.
D18.02	Hemangioma of intracranial structures and any site
D32.-	Benign neoplasm of meninges (cerebral, spinal and unspecified)
D33.-	Benign neoplasm of brain and other parts of central nervous system
D35.2 - D35.4	Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland
D42.-, D43.-	Neoplasm of uncertain or unknown behavior of meninges, brain, CNS
D44.3 - D44.5	Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland
D45	Polycythemia vera (9950/3) <i>ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)</i>
D46.-	Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992)
D47.02	Systemic mastocytosis <i>Note: Effective 10/1/2017</i>
D47.1	Chronic myeloproliferative disease (9963/3, 9975/3) <i>ICD-10-CM Coding instruction note: Excludes the following: Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_) Chronic myeloid leukemia BCR/ABL-positive (C92.1_)</i>

[^]International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors EFFECTIVE: 01/01/2021	
ICD-10 Code [^]	Explanation of Code
	<i>Myelofibrosis & Secondary myelofibrosis (D75.81)</i> <i>Myelophthibic anemia & Myelophthibis (D61.82)</i>
D47.3	Essential (hemorrhagic) thrombocythemia (9962/3) <i>Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia</i>
D47.4	Osteomyelofibrosis (9961/3) Includes: Chronic idiopathic myelofibrosis Myelofibrosis (idiopathic) (with myeloid metaplasia) Myelosclerosis (megakaryocytic) with myeloid metaplasia Secondary myelofibrosis in myeloproliferative disease
D47.Z-	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)
D49.6, D49.7	Neoplasm of unspecified behavior of brain, endocrine glands and other CNS
R85.614	Cytologic evidence of malignancy on smear of anus
R87.614	Cytologic evidence of malignancy on smear of cervix
R87.624	Cytologic evidence of malignancy on smear of vagina

1 Note: Report *Pilocytic/juvenile astrocytoma (M-9421)* as 9421/3.

NOTE: Cases with the codes listed below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental list increases casefinding for benign brain and CNS, hematopoietic neoplasms, and other reportable diseases

SUPPLEMENTAL LIST ICD-10-CM EFFECTIVE: 01/01/2021	
ICD-10-CM Code [^]	Explanation of Code
B20	Human immunodeficiency virus [HIV] disease with other diseases
B97.33, B97.34, B97.35	Human T-cell lymphotropic virus, (type I [HTLV-1], type II [HTLV-II], type 2 [HIV 2]) as the cause of diseases classified elsewhere
B97.7	Papillomavirus as the cause of diseases classified elsewhere
C44.01, C44.02	Basal/squamous cell carcinoma of skin of lip
C44.11-, C44.12-	Basal/squamous cell carcinoma of skin of eyelid
C44.21-, C44.22-	Basal/squamous cell carcinoma of skin of ear and external auricular canal
C44.31-, C44.32-	Basal/squamous cell carcinoma of skin of other and unspecified parts of face
C44.41, C44.42	Basal/squamous cell carcinoma of skin of scalp and neck
C44.51-, C44.52-	Basal/squamous cell carcinoma of skin of trunk
C44.61-, C44.62-	Basal/squamous cell carcinoma of skin of upper limb, including shoulder

[^]International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

SUPPLEMENTAL LIST ICD-10-CM	
EFFECTIVE: 01/01/2021	
ICD-10-CM Code^	Explanation of Code
C44.71-, C44.72-	Basal/squamous cell carcinoma of skin of lower limb, including hip
C44.81, C44.82	Basal/squamous cell carcinoma of skin of overlapping sites of skin
C44.91, C44.92	Basal/squamous cell carcinoma of skin of unspecified sites of skin
D10.- - D31.-, D34, D35.0, D35.1, D35.5- D35.9, D36.-	Benign neoplasms (see "must collect" list for reportable benign neoplasms) <i>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</i> <i>Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior / 3 (malignant) to / 1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER.</i>
D3A._	Benign carcinoid tumors
D37. _ - D41. _	Neoplasms of uncertain or unknown behavior (see "must collect" list for reportable neoplasms of uncertain or unknown behavior) <i>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</i>
D44.0 - D44.2, D44.6- D44.9	Neoplasm of uncertain or unknown behavior of other endocrine glands (see "must collect" list for D44.3-D44.5) <i>Note: Screen for incorrectly coded malignancies or reportable by agreement tumors</i>
D47.01	Cutaneous mastocytosis (9740/1) <i>Note: Effective 10/1/2017</i>
D47.09	Other mast cell neoplasms of uncertain behavior <i>Note: Effective 10/1/2017</i>
D47.2	Monoclonal gammopathy <i>Note: Screen for incorrectly coded Waldenstrom's macroglobulinemia</i>
D47.Z2	Castleman disease
D48.-	Neoplasm of uncertain behavior of other and unspecified sites
D49.0 - D49.9	Neoplasm of unspecified behavior (except for D49.6 and D49.7)
D61.1	Drug-induced aplastic anemia (also known as "aplastic anemia due to antineoplastic chemotherapy") <i>ICD-10-CM Coding instruction note: Use additional code for adverse effect, if applicable, to identify drug</i>
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.82	Myelophthisis <i>ICD-10-CM Coding instruction: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)</i>
D63.0	Anemia in neoplastic disease <i>ICD-10-CM Coding instruction: Code first neoplasm (C00-C49)</i>
D64.81	Anemia due to antineoplastic chemotherapy
D69.49, D69.59, D69.6	Other thrombocytopenia <i>Note: Screen for incorrectly coded thrombocytopenia</i>

^International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

SUPPLEMENTAL LIST ICD-10-CM	
EFFECTIVE: 01/01/2021	
ICD-10-CM Code^	Explanation of Code
D70.1	Agranulocytosis secondary to cancer chemotherapy <i>ICD-10-CM Coding instruction: code also underlying neoplasm</i>
D72.1	Eosinophilia (Note: Code for eosinophilia (9964/3). Not every case of eosinophilia is a malignancy. Reportable Diagnosis is "Hypereosinophilic syndrome.")
D75.81	Myelofibrosis (note: this is not primary myelofibrosis [9961/3]) <i>ICD-10-CM Coding instruction note: Code first the underlying disorder, such as: malignant neoplasm of breast (C50. _)</i>
D76.-	Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue
D89.0, D89.1	Other disorders involving the immune mechanism, not elsewhere classified <i>Note: Review for miscodes</i>
D89.4-	Mast cell activation syndrome and related disorders <i>Note: Effective 10/1/2016</i>
E08	Diabetes mellitus due to underlying condition <i>ICD-10-CM Coding instruction note: Code first the underlying condition, such as: malignant neoplasm (C00-C96)</i>
E31.2-	Multiple endocrine neoplasia [MEN] syndromes <i>ICD-10-CM Coding instruction: Code also any associated malignancies and other conditions associated with the syndromes</i>
E34.0	Carcinoid syndrome <i>ICD-10-CM Coding instruction: May be used as an additional code to identify functional activity associated with a carcinoid tumor</i>
E83.52	Hypercalcemia
E88.09	Other disorders of plasma-protein metabolism, not elsewhere classified
E88.3	Tumor lysis syndrome (following antineoplastic chemotherapy)
G13.0	Paraneoplastic neuromyopathy and neuropathy <i>ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)</i>
G13.1	Other systemic atrophy primarily affecting central nervous system in neoplastic disease <i>ICD-10-CM Coding instruction note: Code first underlying neoplasm (C00-D49)</i>
G32.8	Other specified degenerative disorders of nervous system in diseases classified elsewhere <i>ICD-10-CM Coding instruction note: Code first underlying disease, such as: cerebral degeneration (due to) neoplasm (C00-D49)</i>
G53	Cranial nerve disorders in diseases classified elsewhere <i>Note: Code first underlying neoplasm (C00-D49)</i>
G55	Nerve root and plexus compressions in diseases classified elsewhere <i>ICD-10-CM Coding instruction note: code also underlying disease, such as neoplasm (C00-D49)</i>
G63	Polyneuropathy in diseases classified elsewhere <i>ICD-10-CM Coding instruction note: Code first underlying disease, such as: neoplasm (C00-D49)</i>

^International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

SUPPLEMENTAL LIST ICD-10-CM	
EFFECTIVE: 01/01/2021	
ICD-10-CM Code^	Explanation of Code
G73.1	Lambert-Eaton syndrome in neoplastic disease <i>ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)</i>
G89.3	Neoplasm related pain (acute)(chronic)
G99.2	Myelopathy in diseases classified elsewhere <i>ICD-10-CM Coding instruction: Code first underlying disease, such as: neoplasm (C00-D49)</i>
H47.42	Disorders of optic chiasm in (due to) neoplasm <i>ICD-10-CM Coding instruction: Code also underlying condition</i>
H47.52-	Disorders of visual pathways in (due to) neoplasm <i>ICD-10-CM Coding instruction: Code also underlying condition</i>
H47.63-	Disorders of visual cortex in (due to) neoplasm <i>ICD-10-CM Coding instruction: Code also underlying condition</i>
J34.81	Nasal mucositis (ulcerative)
J91.0	Malignant pleural effusion <i>ICD-10-CM Coding instruction: Code first underlying neoplasm</i>
J93.12	Secondary spontaneous pneumothorax <i>ICD-10-CM Coding instruction: Code first underlying condition, such as: Malignant neoplasm of bronchus and lung (C34._) Secondary malignant neoplasm of lung (C78.0_)</i>
K12.31	Oral mucositis (ulcerative) due to antineoplastic therapy
K12.33	Oral mucositis (ulcerative) due to radiation
K22.711	Barrett's esophagus with high grade dysplasia
K62.7	Radiation proctitis
K62.82	Dysplasia of anus (AIN I and AIN II)
K92.81	Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)
M36.0	Dermato(poly)myositis in neoplastic disease <i>ICD-10-CM Coding instruction: Code first underlying neoplasm (C00-D49)</i>
M36.1	Arthropathy in neoplastic disease <i>ICD-10-CM Coding instruction: Code first underlying neoplasm, such as: Leukemia (C91-C95), malignant histiocytosis (C96.A), multiple myeloma (C90.0)</i>
M84.5-	Pathologic fracture in neoplastic disease <i>ICD-10-CM Coding instruction: Code also underlying neoplasm (C00-D49)</i>
M90.6-	Osteitis deformans in neoplastic disease <i>ICD-10-CM Coding instruction: Code first the neoplasm (C40._, C41._)</i>
N42.3	Dysplasia of prostate (PIN I and PIN II)
N76.81	Mucositis (ulcerative) of vagina and vulva
N87.-	Dysplasia of cervix uteri (CIN I and CIN II)
N89.0, N89.1, N89.3	Vaginal dysplasia (VIN I and VIN II)
N90.0, N90.1, N90.3	Vulvar dysplasia (VAIN I and VAIN II)
O01.-	Hydatidiform mole

^International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

SUPPLEMENTAL LIST ICD-10-CM	
EFFECTIVE: 01/01/2021	
ICD-10-CM Code^	Explanation of Code
	<i>Note: Benign tumor that can become malignant. If malignant, report as Choriocarcinoma (9100/3,) malignancy code in the C00- C97 range</i>
O9A.1-	Malignant neoplasm complicating pregnancy, childbirth and the puerperium (conditions in C00-C96) <i>ICD-10-CM Coding instruction: Use additional code to identify neoplasm</i>
Q85.0-	Neurofibromatosis (nonmalignant) (9540/1) <i>Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable</i>
R18.0	Malignant ascites <i>ICD-10-CM Coding instruction: Code first malignancy, such as: Malignant neoplasm of ovary (C56._), secondary malignant neoplasm of retroperitoneum and peritoneum (C78.6)</i>
R53.0	Neoplastic (malignant) related fatigue <i>ICD-10-CM Coding instruction: Code first associated neoplasm</i>
R59.-	Enlarged lymph nodes
R85.6-	Abnormal findings on cytological and histological examination of digestive organs <i>Note: see "must collect" list for R85.614</i>
R87.61-, R87.62-	Abnormal findings on cytological/histological examination of female genital organs <i>Note: see "must collect" list for R87.614 and R87.624</i>
R92.-	Abnormal findings on diagnostic imaging of breast
R97.-	Abnormal tumor markers
T38.6-	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified
T38.8-, T38.9-	Poisoning by hormones and their synthetic substitutes
T45.1-	Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs
T45.8-, T45.9-	Poisoning by primary systemic and hematological agent, unspecified
T66	Unspecified effects of radiation
T80.1	Vascular complications following infusion, transfusion and therapeutic injection
T80.2-	Infections following infusion, transfusion and therapeutic injection
T80.810	Extravasation of vesicant antineoplastic chemotherapy
T80.818	Extravasation of other vesicant agent
T86.0	Complications of bone marrow transplant <i>ICD-10-CM Coding instruction: Use addition code to identify other transplant complications, such as: malignancy associated with organ transplant (C80.2) or post-transplant lymphoproliferative disorders (PTLD) (D47.Z1)</i>
Y63.2	Overdose of radiation given during therapy
Y84.2	Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Z03.89	Encounter for observation for other suspected diseases and conditions ruled out

^International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.

WASHINGTON STATE CANCER REGISTRY
2021 Case Finding List Effective
01/01/2021

SUPPLEMENTAL LIST ICD-10-CM	
EFFECTIVE: 01/01/2021	
ICD-10-CM Code^	Explanation of Code
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment) <i>ICD-10-CM Coding instruction: Use additional code to identify the personal history of malignant neoplasm (Z85._)</i>
Z12.-	Encounter for screening for malignant neoplasms
Z13.0	Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Z15.0	Genetic susceptibility to malignant neoplasm <i>ICD-10-CM Coding instruction: Code first, if applicable, any current malignant neoplasm (C00-C75, C81-C96); Use additional code, if applicable, for any personal history of malignant neoplasm (Z85._)</i>
Z17.0, Z17.1	Estrogen receptor positive and negative status <i>ICD-10-CM Coding instruction: Code first malignant neoplasm of breast (C50._)</i>
Z40.0-	Encounter for prophylactic surgery for risk factors related to malignant neoplasms
Z42.1	Encounter for breast reconstruction following mastectomy
Z48.3	Aftercare following surgery for neoplasm <i>ICD-10-CM Coding instruction: Use additional code to identify the neoplasm</i>
Z48.290	Encounter for aftercare following bone marrow transplant
Z51.0	Encounter for antineoplastic radiation therapy
Z51.1-	Encounter for antineoplastic chemotherapy and immunotherapy
Z51.5, Z51.89	Encounter for palliative care and other specified aftercare
Z79.81-	Long term (current) use of agents affecting estrogen receptors and estrogen levels <i>ICD-10-CM Coding instruction: Code first, if applicable, malignant neoplasm of breast (C50._), malignant neoplasm of prostate (C61)</i>
Z80.-	Family history of primary malignant neoplasm
Z85.-	Personal history of malignant neoplasm <i>ICD-10-CM Coding instruction: Code first any follow-up examination after treatment of malignant neoplasm (Z08)</i>
Z86.0-, Z86.01-, Z86.03	Personal history of in situ and benign neoplasms and neoplasms of uncertain behavior
Z92.21, Z92.23, Z92.25, Z92.3	Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation)
Z94.81, Z94.84	Bone marrow and stem cell transplant status

^International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM)

*Washington State Cancer Registry uses the ICD-10-CM Casefinding list posted on the SEER website, at <https://seer.cancer.gov/tools/casefinding>. This is adjusted for Washington State Cancer Registry to reflect additional NPCR central cancer registry reporting requirements.